



Beke et al. *N Eng J Med*. 2014 Jul 10;371(2):130-9

Clinical Update:

Dupilumab

- ☐ Inclusion: Age > 18, Chronic AD > 3 yrs, high scores, >10% BSA of AD, h/o inadequate response to tx
- ☐ Exclusion: acute/chronic infections, significant co-morbidities, recent immunosuppressive tx
- ☐ 12 weeks of weekly injections vs. placebo

Results

Pre- And Post-Treatment: Patient Treated With Dupilumab 300 mg Weekly

Baseline:

- IGA score: 4
- BSA affected: 86.5%
- EASI score: 51.5
- Pruritus NRS: 7
- AD duration: 48 years



Week 16



Week 16:

- IGA score: 1
- BSA affected: 2.5%
- EASI score: 3.1
- Pruritus NRS: 1.6

Example of a patient who achieved IGA 1 in the clinical trial and is not representative of all patients. Individual results did vary. Photo used with permission.

IGA, Investigator Global Assessment; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NRS, Numerical Rating Scale.